Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Primmune Therapeutics

Request full access

Primmune Therapeutics is a Biotechnology company

San Diego, United StatesFounded 2017Biotech & Life Sciences

About Primmune Therapeutics

Primmune Therapeutics, a clinical-stage biotechnology firm established in 2017, is focused on developing orally administered small molecules to modulate the innate immune system for therapeutic benefit in oncology and virology. The company was co-founded by James Appleman, Ph.D., Paulo Rangel, and Stephen Webber, Ph.D. The leadership team's background is deeply rooted in drug discovery and immunotherapy. Dr. Appleman, the Chief Scientific Officer, previously co-founded eFFECTOR Therapeutics and played a key role at Anadys Pharmaceuticals in the development of ANA773, a novel TLR7 agonist, providing him with direct experience in the company's core area of focus. President and CEO Charles McDermott brings extensive executive experience from life sciences companies like Impact Biomedicines, which was acquired by Celgene, and Kala Pharmaceuticals.

The company's business model is centered on the research and development of proprietary drug candidates, with a strategy of advancing these assets through clinical trials to demonstrate safety and efficacy. Primmune operates as a venture-backed private entity, having secured significant funding to advance its pipeline. The company has raised a total of $51.4M over several rounds, including a Series A financing of $31.4 million, with investors such as CAM Capital, Polaris Partners, Bioqube Ventures, and Samsara BioCapital. Its goal is to partner with larger pharmaceutical companies for late-stage development and commercialization or to be an acquisition target, a path familiar to its executive team.

Primmune's lead product candidate is PRTX007, an orally administered, small molecule agonist of Toll-like receptor 7 (TLR7). TLR7 is a sensor in the innate immune system that detects single-stranded RNA from viruses. PRTX007 is engineered to systemically activate the innate immune response in a controlled manner. A key feature of PRTX007 is its ability to stimulate plasmacytoid dendritic cells (pDCs) to produce a poly-interferon response, which is critical for antiviral and anti-tumor activity, without causing a surge in pro-inflammatory cytokines like IL-6 and TNFα that can lead to dose-limiting toxicities. This 'tuned' immune activation allows for chronic dosing, potentially making it an ideal combination therapy partner for checkpoint inhibitors in cancer treatment, aiming to improve response rates and durability for patients who do not respond to current immunotherapies. In addition to oncology, Primmune is developing PRTX007 as a broad-spectrum antiviral. The company was awarded a contract of over $22 million from the Defense Threat Reduction Agency (DTRA) to develop PRTX007 for Lassa fever and other hemorrhagic viruses.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
San Diego, United States
Employees
10
Open positions
None listed
Dealroom signal
75.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2026 $8.6M $34M Oberland Capital · Samsara BioCapital · Bioqube Ventures ↗
SERIES AOther financing Nov 2021 $8.4M $34M Undisclosed —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Primmune Therapeutics website traffic

Latest recorded traffic for Primmune Therapeutics is 2.8K monthly website visits, up 330.8% over the last three months. Primmune Therapeutics's team grew 0% over the past year.

Latest monthly visits2.8K 3-month web change+330.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Primmune Therapeutics in the San Diego ecosystem

Live from Dealroom

The Primmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • CAM Capital
  • BioRock Ventures
  • BioBrit

Series A5 investors entered at this stage

  • Polaris Partners
  • Oberland Capital
  • McDermott International
  • Samsara BioCapital
  • Bioqube Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Primmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Primmune Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.